Conference Reports for NATAP

HepDART 2011 December 4, 2011 - December 8, 2011 Kauai, HI, USA Back

Host targeting antiviral (HTA) alisporivir presents a high barrier to resistance both in vitro and in HCV patients with no cross-resistance to DAAs       Reported by Jules Levin   Kai Lin, Ph.D.   "Resistance is Futile" - a Satellite Mini-symposium at HepDART 2011 December 4th, 2011   AASLD: In Vitro Assessment of Potential Drug-Drug Interactions Between Telaprevir and Cyclophilin Inhibitors in the Treatment of Chronic Hepatitis C - (11/22/11)